大型社区论坛之刷刷论坛 - 给您带来真实、丰富、温馨的网上社区!  

刷刷论坛

 找回密码
 立即注册

QQ登录

只需一步,快速开始

使用新浪微博登录

一号多站,快速登录

大秀场

杀得好gas的热度荣华富贵

查看: 116|回复: 0
  • 0威望
  • 996积分
  • 728帖子
    • 等级 4高级会员
    发表于 2018-7-19 11:19:14 |显示全部楼层

    杀得好gas的热度荣华富贵 [复制链接]

    In the first half of 2018, the FDA approved 17 new drugs, 12 of which were the first in the world, and the rest were mostly the first in the EU. As for the distribution of the therapeutic field, the anticancer drug fever has not been reduced. There are 7 products: the first approved Erleada of Janssen and Lutathera of Novartis, and the ZYTIGA of Yangsen who expanded the indication, the Imfinzi of AstraZeneca, and the Lilly. Verzenio, Amgen's Blincyto, and Seattle Genetics' Adcetris.

    Carrelixuzumab for injection is a humanized anti-PD-1 monoclonal antibody that binds to the human PD-1 receptor and blocks the PD-1/PD-L1 pathway, thereby restoring the body's anti-tumor immunity. Form the basis of cancer immunotherapy. It is indicated for the treatment of patients with relapsed/refractory classic Hodgkin's lymphoma who have previously received at least two-line systemic therapy (including autologous hematopoietic stem cell transplantation). Upon inquiry, there are currently no similar products approved for listing in China. The similar products listed abroad include Keytruda (Common name: Pembrolizumab) of Merck and Bristol-Myers Squibb's Opdivo(common name: Nivolumab), both in 2014. Approved by the FDA. In addition to Hengrui Medicine, domestic companies such as Cinda Bio, Junshi Bio, Bristol-Myers Squibb, and Merck East submitted domestic listing applications for similar products.
    http://www.anjianyaoye.com/

    使用道具 举报

    发表回复

    您需要登录后才可以回帖 登录 | 立即注册

    发帖时请遵守我国法律,网站会将有关你发帖内容、发帖时间以及你发帖时的IP地址的记录保留至少60天,并且只要接到合法请求,即会将这类信息提供给有关政府机构。
    回顶部